BCAS3 and cancer: Table 1 contains a selection of the somatic mutations that altered miRNA targeting and met these criteria. We also examined tissue- and cancer-specific miRNA expression to identify miRNAs that have been shown to be highly expressed in the particular tissue or cancer in which the somatic mutations were identified (Table S1). Several of the somatic mutations in Table 1, including those in TAL1, BMPR1B, KDM5A, SCG3, and BCAS3 impacted target sites of miRNAs that have been shown to be expressed in the same tissue in which the miRNA was identified.